top of page

6th Forum:

Co-Hosting "Korea Rise: New Strategies Transforming Korean Biopharma and Unparalleled Opportunities for Collaboration"

September 27, 2016
1:00 PM - 5:00 PM
Yale Club Manhattan, Trumbull Room 18th FL


1:00-1:30 PM      Luncheon Reception  


1:30-1:35 PM      Opening Statement 

DoHyun Cho, PhD

CEO and President, W Medical Strategy Group / Chairman, New York Health Forum


1:35-1:40 PM      Congratulatory Remark 

Ki Young Sohn

CEO and Chairman, Enzychem Lifesciences


1:40-2:45 PM     Session 1

"Collaboration Status, Strategies, and Cases: Korean and Global Pharma” 

  • Kimberly Ha, Senior Director, FTI Consulting (Moderator)

  • Han Bang, Director, CMIC USA

  • Tae Sik Han, Director, KOTRA

  • Judith Kim, Chair of IP Practice, Rubin and Rudman, LLP

  • S.H. Hwang, Director, Pfizer, USA


2:45-3:15 PM     SPECIAL SESSION

“Competitiveness of Chungbuk Province as a Biopharma Hub” 

Joe McManemin, MD, JD, EVP, W Medical Strategy Group (Moderator)

Special Remark 

Honorable Mun-Sik Seol, Vice Governor of Chungbuk Province

Special Presentation

Jungmee, Sohn, PhD, Chungbuk Province


3:15-3:45 PM      NETWORKING BREAK  


3:45-4:45 PM     Session 2 

“Key trends of Global biopharma: Collaboration and beyond” 

  • Joe McManemin, MD, JD, EVP, W Medical Strategy Group (Moderator)

  • Alexander Fleming, MD, CEO, Kinexum

  • Les Funtleyder, Portfolio Manager, E Squared Partner

  • Richard Poska, PharmD, CEO, Flexo, LLC

  • Marc Ullman, Of Counsel, Rivkin Radler Law firm



MOU Ceremony between WMSG and Chungbuk Province

MOU Ceremony between StemCutis and Chungbuk Province


DoHyun Cho, PhD

CEO and President, W Medical Strategy Group | Chairman, New York Health Forum

DoHyun Cho is currently the President and CEO of W Medical Strategy Group. Before current position, DoHyun was the Director General of a Korean government agency, KHIDI’s USA operation in New York for several years. He served as the Advisory Member for the Asia-Pacific Economic Cooperation (APEC) Harmonization Center, Korean government delegate for APEC LSIF, a representative for Korea-US Business Council, Steering Committee member for Korean American Chamber of Commerce.


Ki Young Sohn

CEO and Chairman, Enzychem Lifesciences


Ki Young Sohn is CEO and Chairman of biopharmaceutical company Enzychem Lifesciences Corporation, number one leading company in KONEX stock market of Korea. He served as chairman of Bridget Lifesciences Corporation and was former professor at International Management Institute of Federation of Korean Industries. He also served as a director for Samil Accounting Corporation now known as PWC.

kimberly ha.jpeg

Moderator - Kimberly Ha

Senior Director, FTI Consulting


Kimberly Ha is currently Senior Director at FTI Consulting, Strategic Communications. Her focus area is Capital Markets and Healthcare. She was previously Global Editor for BioPharm Insight, an independent business intelligence product launched by the Financial Times Group. Kimberly has been a panelist and moderator at major healthcare conferences and events. ​


Han Bang

Director, CMIC USA


Han Bang is an experienced international business executive and works for CMIC USA Corporation, a Japan based Global CRO/CMO Company. He was also the former President of CMIC Korea. Before joining CMIC, he worked for several Korean pharmaceutical companies such as LG and Yuhan, and served as US head for JW and other Korean biopharma companies. He is known as an expert in business development of bio-health industry. He learned Business in So-Gang University in South Korea and majored in international business.


Tae Sik Han

Director, KOTRA


Taesik Han is the director of foreign direct investment of KOTRA New York since Aug. 2014. He is responsible for foreign direct investment promotion from the US to Korea and M&A activity from Korean SME(Small and Medium size Enterprise) to US firms in US Atlantic area. Before he moved to New York office in Feb. 2013, he joined KOTRA HQ in Seoul from 2010 and was a member of marketing strategy team for Korean SME. He graduate from Seoul National University's Department of Economics and also earned a master degree in international trade in economics.

judith 6.jpg

Judith Kim, JD

Chair of Intellectual Property Practice, Rubin and Rudman LLP


Judith Kim is a Partner in Rubin and Rudman’s Washington, DC office and Chair of the firm’s Intellectual Property Practice.  For over 20 years, She has counseled clients innovating in pharmaceuticals, biotechnology, immunology, diagnostics, biofuel, food products, nutraceuticals, cosmetics, and personal care. She is also an Adjunct Professor at Sogang University Law School in Korea. Prior to joining Rubin and Rudman, she was a senior partner at a leading IP law firm, where she led legal teams in patent portfolio management, inter partes disputes, licensing and related IP counseling.

sunghye 6.jpg

Sung-Hye Hwang

External Partnerships Lead, Emerging market in Pfizer Innovation Health, Pfizer Inc


Sung-Hye Hwang is Corporate Affairs and Health & Value director at Pfizer Korea and responsible for government relations, policy/environment shaping for market access, patients advocacy activity, and external communications with media, medical & pharmaceutical societies, NGOs, etc. She became Corporate Affairs director since 2010 and expanded her role to Corporate Affairs/H&V lead in 2015. She is also taking the leadership role at KRPIA and AMCHAM. She has joined Pfizer Korea as a Government Relations Manager in 2008, and also served as Healthcare Policy Manager and Access Manager. Prior to joining Pfizer, she was a journalist in Chosun Daily Newspaper for 13 years.


Mun-Sik Seol

Vice Governor of Chungbuk Province


Mun-Sik Seol is currently a Vice Governor for Political Affairs at Chungbuk Provincial Government since 2012. Under his leadership, Chungbuk has consistently tried its best when it comes to helping companies establish cooperative partnerships with the international community. Prior to becoming a Vice Governor, he was a Marketing Director at Yeosu World Expo Organizing Committee. Mun-Sik Seol also has served at the Secretary Office for President of Republic of Korea, and Planning and Budget Office at the Ministry of Finance. He has participated in training program at the Alabama State Government and majored in economy at Seoul National University.


Jungmee Sohn, PhD

Manager of Foreign Investment Promotion at Chungbuk Provincial Government


Jungmee Sohn is currently a manager of Foreign Investment Promotion/International Cooperation at Chungbuk Provincial Government since 2001. She has a previous experience of teaching practical English at Konkuk University and social studies at Daewon High School. She also has an experience as an accountant at Los Angeles Samuel B. Choi, CPA. She earned her PhD in English Literature at Chungbuk National University in 2012 and earned a Master’s degree in English Education in 2001 at Sogang University following her major in computer science at Graduate School of Kent State University in Ohio. She originally majored in social studies at Ewha Woman’s University in Seoul.


Moderator - Joseph P. McMenamin, MD, JD, FCLM

Executive Vice President, W Medical Strategy Group


Joseph P. McMenamin is an Executive VP and Chief Legal Officer with W Medical Strategy Group. He has more than 20 years’ experience in defending pharmaceutical, medical device, and biotech companies against a variety of allegations in state and federal court. He also advises clients on managing risks related to telemedicine, corporate use of the internet, social media, communications between life science companies and physicians, compliance with FDA regulations. For much of his career, He practiced as a partner at McGuireWoods LLP.


Alexander Fleming, MD

CEO, Kinexum


Alexander Fleming, also known as Zan, MD is Founder and Chief Executive Officer at Kinexum, Inc. since 2003. He is also founder and CEO of Exsulin and a clinical professor of medicine at Case Western University. He is the lead author of the book, “Optimizing Development of Therapies for Diabetes” and served as a reviewer and supervisory medical officer at the US FDA. He helped to shape a number of FDA policies and practices related to therapeutic review and regulatory communication. His regulatory and technical expertise has been requested in numerous international settings including the World Health Organization. He conceived and led the first FDA pilot project to utilize the internet for regulatory communication.


Les Funtleyder, MPH

Healthcare Portfolio Manager, E Squared Capital Management


Les Funtleyder is a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. He is also a consulting partner to Bluecloud Health, a Sub-Saharan healthcare private equity fund, and on the board of several healthcare companies and foundations. He is also currently an Adjunct Professor of Public Health at Columbia. Prior to E Squared, he was the Director of Strategic Investments for Opko Health, Phil Frost's holding company. He also wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services (McGraw Hill).


Richard Poska, PharmD

CEO, Flexo LLC


Richard Poska is managing director of Flexo where he provides CMC consulting services to the pharmaceutical industry. His 20 years of regulatory experience includes submitting NDAs and multiple INDs and has negotiated and submitted post approval supplements for over a dozen marketed products. As a director at Abbott, he was also responsible for FDA and other regulatory agency audits.  His expertise includes regulatory CMC strategies for investigational and marketed products and regulatory intelligence. He is internationally known for his presentations and publications on the application of microwave drying to pharmaceutical processing.


Marc S. Ullman, JD

Of Counsel, Rivkin Radler LLP


Marc S. Ullman is an Of Counsel at Rivkin Radler LLP. He practiced with one of New York’s leading firms for ten years, where he represented clients in both federal and state prosecutions, as well as numerous related civil matters and other litigations. He has also represented clients in a number of complex adversarial proceedings with the FDA. In addition, Marc speaks frequently at various events and also presented and moderated a panel discussion entitled, “Crisis Management and Risk Reduction” on several occasions, including at the Metropolitan Association for Food Protection’s annual meeting in October 2002.

bottom of page